Botanical species · safety record

Huperzia serrata

The EFSA Compendium of Botanicals holds 15 constituent measurements and 4 adverse-effect records for Huperzia serrata. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Huperzia serrata (Thunb.) Trevis.

15Constituent measurements

4Safety records

7Cited sources

142Licensed products (Canada)

Also recorded as

Lycopodium serratum Thunb.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 142 licensed products naming Huperzia serrata as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Fresh

Source material stated

Aerial parts (standardized extract)
Fruit
Herb extract
Herb top
Huperzia serrata
Huperzia serrata - whole plant
Leaf
New material

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Alkaloids	Unspecified	—	—	Unspecified	Resolve DOI
Alkaloids	Live plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Huperzine a	Unspecified	Solvent extraction	12.46 Milligram/litre	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Huperzine a	Unspecified	Solvent extraction	≤ 2.03 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Huperzine a	Unspecified	Solvent extraction	≥ 1.66 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Huperzine a	Stem / stalk	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Huperzine a	Live plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Huperzine b	Unspecified	Solvent extraction	5.66 Milligram/litre	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Huperzine b	Live plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Huperzine b	Unspecified	Solvent extraction	≥ 0.8 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Huperzine b	Unspecified	Solvent extraction	≤ 0.91 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Lycodine	Unspecified	—	—	Unspecified	Resolve DOI
Lycopodine	Live plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Quinolizidine alkaloids	Stem / stalk	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Digestive	Digestive	Live plants	Solvent extraction	Saccharomyces cerevisiae (as organism)	In vitro	Resolve DOI
Digestive	Digestive	Live plants	Solvent extraction	Saccharomyces cerevisiae (as organism)	In vitro	Resolve DOI
Digestive	Digestive	Live plants	Solvent extraction	Saccharomyces cerevisiae (as organism)	In vitro	Resolve DOI
Hepatotoxicity	Liver	—	—	Human (as organism)	Case report	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Liu, Yu-Chen., Zhang, Zhi-Jun., Su, Jia., Peng, Li-Yan., Pan, Lu-Tai., Wu, Xing-De., Zhao, Qin-Shi. Lycodine-Type Lycopodium Alkaloids from the Whole Plants of Huperzia serrata. . Natural products and bioprospecting, 2017. DOI
Li, XN., Ma, RY., Su, HH., Sun, HH., Ma, GH., Su, ZG., Zha, SH. Rapid purification of huperzine A and B with two polystyrene based resins by preparative low-pressure liquid chromatography . Journal of liquid chromatography & related technologies, 2006, vol. 29, no. 4, p. 569-582. DOI
Ying, You-Min., Liu, Xiao-Sa., Tong, Cui-Ping., Wang, Jian-Wei., Zhan, Zha-Jun., Shan, Wei-Guang. Lycopodium Alkaloids from Huperzia serrata. Helvetica chimica acta, 2014, vol. 97, no. 10, p. 1433-1439. DOI
Ernst, E. Adverse effects of unconventional therapies in the elderly: A systematic review of the recent literature. Journal of the american aging association, 2002, vol. 25, no. 1, p. 11-20. DOI
Ferreira, Ana., Rodrigues, Marcio., Fortuna, Ana., Falcao, Amilcar., Alves, Gilberto. Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology . Phytochemistry reviews, 2016, vol. 15, no. 1, p. 51-85. DOI
Zhang, Hongchao., Liang, Hao., Kuang, Pengqun., Yuan, Qipeng., Wang, Yan. Simultaneously preparative purification of Huperzine A and Huperzine B from Huperzia serrata by macroporous resin and preparative high performance liquid chromatography . Journal of chromatography b-analytical technologies in the biomedical and life sciences, 2012, vol. 904, p. 65-72. DOI
Shan, Wei-Guang., Ren, Feng-Yun., Ying, You-Min., Tong, Cui-Ping., Zhan, Zha-Jun. A new lycopodine alkaloid from Huperzia serrata. Journal of chemical research, 2012, no. 1, p. 15-16. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature